Levoleucovorin Calcium Injection, Solution
NDC Package 70436-210-80
Package Information
Levoleucovorin Calcium (levoleucovorin injection) injection is levoleucovorin injection is indicated for:rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma.diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients.the treatment of adults with metastatic colorectal cancer in combination with fluorouracil.Limitations of Use:Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12,because of the risk of progression of neurologic manifestations despite hematologic remission. This formulation utilizes a injection, solution delivery system. Marketed by Slate Run Pharmaceuticals, this product is identified by NDC 70436-210 and is authorized under FDA application ANDA217314.
Identification & Billing
- RxCUI: 1720765 - LEVOleucovorin 175 MG in 17.5 mL Injection
- RxCUI: 1720765 - 17.5 ML levoleucovorin 10 MG/ML Injection
- RxCUI: 1720765 - levoleucovorin (as levoleucovorin calcium) 175 MG per 17.5 mL Injection
- RxCUI: 1720765 - levoleucovorin 175 MG per 17.5 mL Injection
- RxCUI: 1720773 - LEVOleucovorin 250 MG in 25 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70436 - Slate Run Pharmaceuticals
- 70436-210 - Levoleucovorin Calcium
- 70436-210-80 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 25 mL in 1 VIAL, SINGLE-DOSE
- 70436-210 - Levoleucovorin Calcium
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70436-210-80 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 25 ml in 1 vial, single-dose of Levoleucovorin Calcium, a human prescription drug labeled by Slate Run Pharmaceuticals. This injection, solution is formulated for intravenous use and contains levoleucovorin calcium as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Slate Run Pharmaceuticals on August 01, 2023. The current certification is valid through December 31, 2026.
How is this Slate Run Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70436021080. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.